Clinical Trials on Intracerebral Hemorrhage in South Africa

Total 565 results

AbbVie

Active, not recruiting

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Puerto Rico
Sanofi

Completed

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)

Plasma Cell Myeloma

United States
AbbVie

Terminated

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Cancer | Multiple Myeloma (MM)

United States, Australia, France, Israel, Japan, Spain, Taiwan
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada
Oncotherapeutics

Unknown

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
Bristol-Myers Squibb
Abbott

Terminated

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Newly Diagnosed, Previously Untreated Multiple Myeloma

United States, Poland, Italy, Greece
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Baxalta now part of Shire

Active, not recruiting

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Hemophilia B

United States
Pharmacyclics LLC.

Completed

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Shire
Takeda Development Center Americas, Inc.

Completed

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (SOAR-HI)

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

United States, Spain, Canada, United Kingdom, France, Germany, Italy
Novo Nordisk A/S

Available

Compassionate Use of Concizumab if You Have Haemophilia

Congenital Haemophilia

United States, Bulgaria, Sweden
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma, Plasma Cell Leukemia

United States
Baxalta now part of Shire

Completed

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

United States, Spain, Australia, Taiwan, Czechia, Turkey, Ukraine, Netherlands, Italy, United Kingdom, Austria, Germany, Russian Federation
Novartis Pharmaceuticals

Completed

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants (Z-MARK)

Multiple Myeloma

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Relapsed or Refractory Multiple Myeloma

United States, Turkey, Canada, Netherlands, Australia, Germany, France
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Multiple Myeloma | Non-Small Cell Lung Cancer | Solid Tumors

United States
Pfizer

Active, not recruiting

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Hemophilia A | Hemophilia B

United States, Spain, Canada, China, Korea, Republic of, Hong Kong, Serbia, Taiwan, Turkey, France, Oman, Saudi Arabia, Japan, India, South Africa, Mexico, Croatia, Italy, Bulgaria, Russian Federation
Sanofi

Completed

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

France, Spain, Belgium, Australia, United States, Japan
AbbVie

Terminated

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Germany, Israel, Japan, Spain
ApcinteX Ltd
Centessa Pharmaceuticals plc

Recruiting

A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors (PRESent-3)

Hemophilia B | Hemophilia B With Inhibitor

United States, Spain, Australia, Taiwan, France, Armenia, Germany
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Pfizer

Active, not recruiting

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Hemophilia A | Hemophilia B

United States, Canada, Spain, Australia, Korea, Republic of, Taiwan, Brazil, Italy, Japan, Turkey, Germany, United Kingdom, Saudi Arabia, France, Sweden, Belgium, Greece, Israel
Novartis Pharmaceuticals

Completed

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Bone Neoplasms

Australia
Taunton and Somerset Hospital

Completed

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Lymphoma

Australia, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Amgen

Terminated

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (AMG420)

Relapsed and/or Refractory Multiple Myeloma

United States, Japan, Belgium, Australia, Switzerland
Celgene

Approved for marketing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

Multiple Myeloma

United States, Canada
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Sanofi

Recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Czechia, Japan, Australia, Brazil, Greece, Portugal
National Cancer Institute (NCI)

Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma and other conditions

United States
Celgene

Completed

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Spain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
Bayer

Withdrawn

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Multiple Myeloma

Belgium, Spain, Korea, Republic of, Taiwan, United States, Australia, Germany, Israel, Italy, Greece, Canada
BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, Australia, France, China, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Bristol-Myers Squibb

Completed

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma

United States
Sanofi

Completed

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
Novo Nordisk A/S

Completed

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United States, Spain, Taiwan, Turkey, Poland, Croatia, Italy, Malaysia, Brazil, United Kingdom, Hungary, Israel, Thailand, Japan, South Africa, Canada, France, Argentina
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Bristol-Myers Squibb
AbbVie; Celgene

Completed

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Multiple Myeloma

United States, Germany, Italy, Greece, Netherlands, Australia, Spain, Poland, Canada, France, Japan
Incyte Corporation

Terminated

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

MPN (Myeloproliferative Neoplasms)

United States
BeiGene

No longer available

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Waldenström Macroglobulinemia

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada
CSL Behring

Completed

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States
Novo Nordisk A/S

Recruiting

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)

Haemophilia A and B With and Without Inhibitors

United States, Spain, Italy, Estonia, Thailand, Canada, India, Malaysia, United Kingdom, Turkey, South Africa, Lebanon, Bosnia and Herzegovina, Bulgaria, France, Greece, Japan, Lithuania, Norway, Poland, Romania, Russian Federation, Swede... and more
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
AbbVie
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, Denmark, France, Germany, Japan
CSL Behring

Completed

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States, Spain
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico

Clinical Trials on Intracerebral Hemorrhage in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations